H. Lundbeck A/S (Lundbeck) today announced that amlenetug has received Fast Track designation from the United States (US) Food and Drug Administration (FDA).

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

Amlenetug received Orphan Drug Designation (ODD) from the US FDA in April 2024, the EMA in May 2021 and SAKIGAKE designation ...

Lundbeck has received the US FDA fast track designation for amlenetug, a potential treatment for multiple system atrophy (MSA ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

A downtown Auburn brewpub has announced that it is closing temporarily due to one of its owners having a terminal illness.

AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms GenePHIT is a clinical ...

A tribute to Simon Townsend, creator of Wonder World, celebrating his contributions to Australian children’s television and ...